Your shopping cart is empty!
Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
Catalog: | HY-B0448 |
Brand: | MCE |
CAS: | 57-41-0 |
MDL | MFCD00005264 |
---|---|
Molecular Weight | 252.27 |
Molecular Formula | C15H12N2O2 |
SMILES | O=C1NC(C(C2=CC=CC=C2)(C3=CC=CC=C3)N1)=O |
Phenytoin is an antiepileptic drug. It is useful to partial seizures and generalized tonic-clonic seizures but not primary generalized seizures such as absence seizures or myoclonic seizures. Phenytoin is believed to protect against seizures by causing voltage-dependent block of voltage-gated sodium channels
[2]
.
Phenytoin has low affinity for resting sodium channels at hyperpolarized membrane potentials
[3]
.
When neurons are depolarized and the channels transition into the open and inactivated states, greater binding and block occur. The inhibitory potency is strongly use dependent, so that block accumulates with prolonged or repetitive activation, such as occurs during a seizure discharge. The blocking of sodium channels by phenytoin is of slow onset. The time course of fast sodium currents is therefore not altered in the presence of the drug and action potentials evoked by synaptic depolarizations of ordinary duration are not blocked. Thus phenytoin is able to selectively inhibit pathological hyperexcitability in epilepsy without unduly impairing ongoing activity. Phenytoin also blocks persistent sodium current and this may be of particular importance in seizure control. Phenytoin is a class 1b antiarrhythmic
[4]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Phenytoin (5,5-Diphenylhydantoin; 60 mg/kg; daily; 28 days ) reduces tumour growth in six week-old female Rag2 -/- Il2rg -/- mice with MDA-MB-231 cells [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT01122940 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Healthy
|
July 2010 | Phase 1 |
NCT04956627 | Bristol-Myers Squibb |
Healthy Participants
|
July 28, 2021 | Phase 1 |
NCT02283827 | Bial - Portela C S.A. |
Epilepsy
|
January 2007 | Phase 1 |
NCT00245037 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms|Precancerous Condition
|
June 2005 | Phase 1|Phase 2 |
NCT00610532 | Jim McAuley|Ohio State University |
Epilepsy
|
March 2006 | Phase 4 |
NCT00146237 | Beersheva Mental Health Center|The Rogosin Institute |
Depression
|
November 2003 | Phase 4 |
NCT01451593 | University College, London|National Multiple Sclerosis Society|Multiple Sclerosis Society of Great Britain and Northern Ireland |
Optic Neuritis|Multiple Sclerosis
|
November 2011 | Phase 2 |
NCT03778996 | Sarcoma Oncology Research Center, LLC|Joseph Ahmed Foundation|Tyme, Inc |
Sarcoma, Ewing|Sarcoma
|
January 3, 2020 | Phase 2 |
NCT05542589 | Cairo University |
Pressure Ulcer
|
March 1, 2022 | Not Applicable |
NCT04573803 | Cambridge University Hospitals NHS Foundation Trust|University of Cambridge |
Traumatic Brain Injury|Post Traumatic Seizures
|
March 1, 2021 | Phase 3 |
NCT02409433 | Lawson Health Research Institute|UCB Pharma GmbH |
Seizures
|
August 2014 | Phase 4 |
NCT01478035 | M. Carmen Cabellos Minguez|Hospital Universitari de Bellvitge|Hospital Vall d´Hebron|Germans Trias i Pujol Hospital|Hospital Clinic of Barcelona|Fundació Institut de Recerca de l´Hospital de la Santa Creu i Sant Pau|Hospitales Universitarios Virgen del Rocío|Hospital Universitario La Paz|Hospital Universitario Ramon y Cajal|Hospital Juan Canalejo|Hospital Mutua de Terrassa|Hospital Universitario Virgen Macarena |
Seizures|Pneumococcal Meningitis
|
November 2011 | Phase 4 |
NCT03196466 | Assistance Publique - Hôpitaux de Paris |
Epilepsy
|
June 19, 2017 | |
NCT01122953 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Healthy
|
April 2010 | Phase 1 |
NCT03269214 | Shiraz University of Medical Sciences|Shahid Beheshti University of Medical Sciences |
Osteonecrosis Due to Drugs, Jaw
|
September 1, 2012 | Not Applicable |
NCT00162461 | Hadassah Medical Organization|United States - Israel Binational Science Foundation |
Healthy
|
August 1998 | Not Applicable |
NCT00004817 | National Institute of Neurological Disorders and Stroke (NINDS)|Harborview Injury Prevention and Research Center|Office of Rare Diseases (ORD) |
Post-Traumatic Seizure Disorder|Head Injuries
|
February 1991 | Phase 3 |
NCT02413658 | Children´s Surgical Center, Cambodia |
Wound|Re-Epithelialization
|
March 2015 | Phase 2 |
NCT00647621 | Mylan Pharmaceuticals Inc|MylanPharma |
Healthy
|
October 2005 | Phase 1 |
NCT04981704 | Spectrum Pharmaceuticals, Inc |
Healthy
|
April 8, 2021 | Phase 1 |
NCT00581893 | University of Iowa |
Cognitive Measures|Driving Simulator Performance
|
August 2005 | Phase 4 |
NCT02707965 | Food and Drug Administration (FDA)|University of Maryland, Baltimore |
Epilepsy
|
June 8, 2017 | Phase 1 |
NCT04845646 | Gannex Pharma Co., Ltd. |
Healthy|NAFLD
|
March 16, 2021 | Phase 1 |
NCT00627575 | GlaxoSmithKline |
Epilepsy
|
February 4, 2008 | Phase 1 |
NCT01680042 | Shahid Beheshti University of Medical Sciences |
Wound Healing|Pain
|
October 2012 | Phase 1 |
NCT00210782 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Ortho-McNeil Neurologics, Inc. |
Epilepsy
|
June 2004 | Phase 3 |
NCT00801931 | Columbia University |
Leukemia|Lymphoma|Neuroblastoma|Immunodeficiencies|Anemia
|
September 6, 2007 | Phase 1|Phase 2 |
NCT02374567 | Hannover Medical School |
Dementia|Depression|Schizophrenia|Psychosomatic Disorders|Anxiety Disorders
|
January 2015 | Phase 3 |
NCT02088957 | UCB BIOSCIENCES, Inc.|PRA Health Sciences|UCB Pharma |
Nonconvulsive Electrographic Seizures
|
March 2014 | Phase 2 |
NCT01730313 | Centers for Disease Control and Prevention|Ministry of Health, Uganda |
Nodding Syndrome
|
February 2016 | Phase 2 |
NCT02939937 | Tehran University of Medical Sciences |
Optic Neuritis
|
March 9, 2017 | Phase 2 |
NCT00366067 | Centre of Chinese Medicine, Georgia|Rea Rehabilitation Centre, Georgia |
Bronchial Asthma
|
August 2006 | Phase 4 |
NCT00000285 | National Institute on Drug Abuse (NIDA)|University of Minnesota |
Cocaine-Related Disorders
|
May 1996 | Phase 1 |
NCT00591006 | University of Texas Southwestern Medical Center |
Healthy
|
January 2008 | Phase 3 |
NCT00226538 | Hadassah Medical Organization |
Healthy Volunteers
|
August 1999 | Not Applicable |
NCT00219479 | Penn State University |
Seizures
|
August 1997 | Phase 4 |
NCT00618436 | University of Cincinnati|Mayfield Clinic & Spine Institute |
Traumatic Brain Injury|Subarachnoid Hemorrhage
|
August 2007 | Phase 4 |
NCT00774306 | Thomas Jefferson University|National Institute of Neurological Disorders and Stroke (NINDS) |
Subarachnoid Hemorrhage
|
April 2009 | Not Applicable |
NCT00598923 | University of Pennsylvania |
Traumatic Brain Injury|Epilepsy
|
November 2004 | Early Phase 1 |
NCT01635829 | Janssen Infectious Diseases BVBA |
Healthy Participants
|
May 2012 | Phase 1 |
NCT04647877 | David J. Kopsky|Princess Beatrix Muscle Foundation|Dr. C.J. Vaillant Fonds|UMC Utrecht |
Chronic Idiopathic Axonal Polyneuropathy
|
September 17, 2020 | Phase 2|Phase 3 |
NCT04176887 | Tanta University |
Comparison|the Efficacy of Levetireacetam|Phenytoin|Management of Pediatric Status Epilepticus
|
January 1, 2019 | Phase 4 |
NCT00333931 | Michael E. DeBakey VA Medical Center|Dr. Thomas A. Kent|Dr. Stacey Holmes|Dr. Su Bailey|Dr. Mark Kunik|Dr. Melinda Stanley |
Impulsive Aggression|Posttraumatic Stress Disorder
|
June 2006 | Not Applicable |
NCT01355068 | Pfizer´s Upjohn has merged with Mylan to form Viatris Inc.|Pfizer |
Healthy
|
May 2011 | Phase 1 |
NCT01878578 | Bial - Portela C S.A. |
Epilepsy
|
November 2002 | Phase 1 |
NCT03632915 | University of Maryland, Baltimore |
Acute Kidney Injury|Renal Insufficiency|Renal Failure|Pharmacokinetics
|
November 20, 2017 | |
NCT02595723 | University of Texas Southwestern Medical Center|The Rogosin Institute |
Cognitive Impairment
|
July 2015 | Phase 4 |
NCT00004403 | Johns Hopkins University|FDA Office of Orphan Products Development |
Epilepsy|Cysticercosis
|
May 2000 | Not Applicable |
NCT00162474 | Hadassah Medical Organization |
Healthy
|
September 2003 | Not Applicable |
NCT01187719 | Radboud University Medical Center |
HIV-infection|Pregnancy|Mother to Child Transmission
|
May 2010 | Phase 2 |
NCT03096522 | Mansoura University |
Anal Fistula
|
February 20, 2017 | Not Applicable |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 50 mg/mL ( 198.20 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 3.9640 mL | 19.8200 mL | 39.6401 mL |
5 mM | 0.7928 mL | 3.9640 mL | 7.9280 mL |
10 mM | 0.3964 mL | 1.9820 mL | 3.9640 mL |
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.